- Home
- ADPT vs OMCL Comparison
ADPT vs OMCL Comparison
Compare ADPT & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- OMCL
- Stock Information
- Founded
- ADPT 2009
- OMCL 1992
- Country
- ADPT United States
- OMCL United States
- Employees
- ADPT N/A
- OMCL N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- OMCL Computer Manufacturing
- Sector
- ADPT Health Care
- OMCL Technology
- Exchange
- ADPT Nasdaq
- OMCL Nasdaq
- Market Cap
- ADPT 1.4B
- OMCL 1.3B
- IPO Year
- ADPT 2019
- OMCL 2001
- Fundamental
- Price
- ADPT $11.48
- OMCL $29.80
- Analyst Decision
- ADPT Strong Buy
- OMCL Buy
- Analyst Count
- ADPT 7
- OMCL 6
- Target Price
- ADPT $10.57
- OMCL $44.83
- AVG Volume (30 Days)
- ADPT 2.2M
- OMCL 477.0K
- Earning Date
- ADPT 07-31-2025
- OMCL 07-31-2025
- Dividend Yield
- ADPT N/A
- OMCL N/A
- EPS Growth
- ADPT N/A
- OMCL N/A
- EPS
- ADPT N/A
- OMCL 0.45
- Revenue
- ADPT $189,527,000.00
- OMCL $1,135,755,000.00
- Revenue This Year
- ADPT $24.46
- OMCL $3.84
- Revenue Next Year
- ADPT $20.25
- OMCL $4.07
- P/E Ratio
- ADPT N/A
- OMCL $66.15
- Revenue Growth
- ADPT 8.61
- OMCL 3.00
- 52 Week Low
- ADPT $3.30
- OMCL $22.66
- 52 Week High
- ADPT $12.43
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- ADPT 63.39
- OMCL 52.87
- Support Level
- ADPT $11.17
- OMCL $28.80
- Resistance Level
- ADPT $12.43
- OMCL $30.57
- Average True Range (ATR)
- ADPT 0.59
- OMCL 0.79
- MACD
- ADPT 0.03
- OMCL 0.08
- Stochastic Oscillator
- ADPT 62.45
- OMCL 73.17
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.